companiesandmarkets.com

Return to Report | Print

Premium Company Profile - Idenix Pharmaceuticals, Inc.

http://www.companiesandmarkets.com/Summary-Company-Profile/premium-company-profile-idenix-pharmaceuticals,-inc.-41243.asp

Report Summary

Introduction

Idenix Pharmaceuticals develops drugs for the treatment of human viral and other infectious diseases. Novartis is the major shareholder of the company owning 56% of Idenix and has development and worldwide marketing rights for Idenix's HBV and HCV franchise.

Scope

  • Contains corporate strategy, value chain presence and SWOT Analysis
  • Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
  • Includes information on suppliers/ partners, shareholding structure and key employees with biographies


    • Highlights

    Idenix currently focuses on the development and commercialization of drugs for the treatment of hepatitis C and human immuno viral infections. The company's only approved product, Tyzeka/Sebivo for the hepatitis B virus, is developed, manufactured and marketed by Novartis and Idenix receives royalties on the product sales

    The company's total revenues increased at a CAGR of 110% from $3 million to $67 million during 2002-2006, representing an absolute growth of +$64 million. As the company launched approved product Tyzeka in October 2006, it recorded $0.6 million of revenues from product sales in fiscal 2006

    Idenix's revenues are forecast to increase from $67 million in 2006 to $198 million in 2010, growing at a CAGR of 31%. This represents an absolute growth of +$131 million during the period. Collaboration and license revenues from Novartis are expected to be the largest contributor to the company's overall revenue growth

    Reasons to Purchase

  • Access all the important information and analysis on the company in a single report
  • Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain
  • Gain access to company's adjusted five year financial data along with key ratios and market capitalization

    • Table of Contents

    TABLE OF CONTENTS
    Overview 1
    Catalyst 1
    Summary 1
    Company Structure 6
    Company Overview and Key Facts 6
    Business Description 7
    History 8
    Locations and Subsidiaries 9
    Company Financials 10
    Stock Market Performance 10
    P&L 11
    Balance Sheet 13
    Cash Flow 13
    Business Segment Performance 14
    Products & Services 15
    Marketed Products 15
    Pipeline Products 16
    Historical Product Sales 17
    AC Forecast Product Sales 17
    Competitors and Strategic Business Relationships 19
    Key Competitors 19
    Key Suppliers 19
    Key Clients 20
    Shareholding Structure 21
    Strategy 22
    Company View 22
    Corporate Strategy 23
    SWOT Analysis 24
    Overview 24
    Strengths 25
    Weaknesses 26
    Opportunities 27
    Threats 28
    Value Chain Analysis 29
    Overview 29
    Discovery and Product Development 29
    Scorecard 30
    Overview 30
    Scorecard Analysis 31
    Key Employees 33
    List of Key Employees 33
    Key Employee Biographies 34
    Financial and Operational Overview 41
    Financial and Operational Overview 41
    APPENDIX 43
    Ask the analyst 43
    Datamonitor consulting 43
    Disclaimer 43


    TABLE OF FIGURES
    Figure 1: Idenix Pharmaceuticals - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) 12
    Figure 2: Idenix Pharmaceuticals - Key Strategic Revenues, 2006-2010 ($ Mn) 18


    TABLE OF TABLES
    Table 1: Idenix Pharmaceuticals - Key Facts 6
    Table 2: Idenix Pharmaceuticals – Locations and Subsidiaries 9
    Table 3: Idenix Pharmaceuticals - Year-End Share Price and Market Capitalization, 2002-2006 ($) 10
    Table 4: Idenix Pharmaceuticals – Key Events Impacting Share Price Performance, 2002-2006 10
    Table 5: Idenix Pharmaceuticals - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) 11
    Table 6: Idenix Pharmaceuticals – Operating Cost Ratio Analysis, 2002-2006 (% of total revenues) 13
    Table 7: Idenix Pharmaceuticals – Balance Sheet, 2002-2006 ($ Mn) 13
    Table 8: Idenix Pharmaceuticals – Cash Flow, 2002-2006 ($ Mn) 13
    Table 9: Idenix Pharmaceuticals - Revenue Breakdown, 2002-2006 ($ Mn) 14
    Table 10: Idenix Pharmaceuticals – Marketed Products 15
    Table 11: Idenix Pharmaceuticals - In-house Pipeline Products 16
    Table 12: Idenix Pharmaceuticals – Forecast Sales, 2006-2010 ($ Mn) 17
    Table 13: Idenix Pharmaceuticals – Key Competitors 19
    Table 14: Idenix Pharmaceutical – Key Suppliers 20
    Table 15: Idenix Pharmaceuticals – Key Clients 20
    Table 16: Idenix Pharmaceuticals - Key Shareholders 21
    Table 17: Idenix Pharmaceuticals - SWOT Analysis Summary 24
    Table 18: Idenix Pharmaceuticals – Value Chain Analysis 29
    Table 19: Idenix Pharmaceuticals – Scorecard 31
    Table 20: Idenix Pharmaceuticals - Key Employees 33
    Table 21: Idenix Pharmaceuticals - Financial and Operational Overview 41